Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Summary

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).

Timeline

Start

2021-10-06

Primary completion

2024-12-27

Completion

2024-12-27

Outcome

Missed primary endpoint

paper Semaglutide did not improve executive function (adjusted Z score difference [semaglutide - placebo]: 0.32, 95% confidence interval [CI]: -0.92 to 1.58, p = 0.60). PMID 41218611 ↗

Publications

• Gill H, Badulescu S, Shah H, Brudner RM, Phan L, Di Vincenzo JD, Tabassum A, Thanarajah SE, Llach CD, Rosenblat JD, McIntyre RS, Mansur RB. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Jul 1;83(7):751-754. doi: 10.1001/jamapsychiatry.2026.0594.
• Badulescu S, Gill H, Shah H, Brudner R, Phan L, Di Vincenzo JD, Tabassum A, Armanyous M, Llach CD, Rosenblat JD, McIntyre RS, Mansur RB. Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med. 2026 Jan 9;7(1):100916. doi: 10.1016/j.medj.2025.100916. Epub 2025 Nov 10.

Drugs

Indications